Back to results
US 2026/0092062 A1Published application
Pyridine carboxamide compounds and their use in treating medical conditions
AssigneeRectify Pharmaceuticals, Inc.
InventorsTodd Bosanac, Nathan Oliver Fuller, Robert Owen Hughes, Guy Bemis, Janeta Valentina Popovici Muller
Life of this patent
Estimating the term…
Abstract
The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
Claims76
A compound represented by Formula I:
- or a pharmaceutically acceptable salt thereof;
- wherein:
- Ring A is a 6-14 membered saturated or partially unsaturated bicyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 6-11 membered saturated or partially unsaturated bicyclic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, an 8-10 membered bicyclic aromatic carbocyclic ring, or phenyl;
- R1 represents independently for each occurrence halo, oxo, —CN, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)CR3, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —O(CR2)3NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —NR(CR2)2OR, —N(R)S(O)2NR2, —N(R)S(O)2R, —CR3, —CH2NR2, —CH2NHCH2CH2OR, —CH2CH2C(O)OR, —CH2C(O)NR2, —CH2CH2R, —CH2CH2OR, —NHCH2CH2OR, —NHC(O)R, —CH2OR, —CH2C(O)NH2, —CH2NHC(O)OCR3, —OCR, C1-4 aliphatic, C1-4 haloaliphatic, or a cyclic group selected from a 3-8 membered saturated monocyclic carbocyclic ring or a 3-8 membered saturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- R2 is hydrogen, halo, —OH, —CN, cyclopropyl, C1-3 alkyl optionally substituted with a group selected from —OH, —NH2, —NH(CH3), and —N(CH3)2, C1-3 haloalkyl, or C1-3 alkoxy;
- R3 is hydrogen, cyclopropyl, or C1-3 alkyl optionally substituted with a group selected from —OH, OMe, —NH2, —NH(CH3), and —N(CH3)2;
- R4 is a cyclic group selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7-12 membered saturated or partially unsaturated bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein R4 is substituted with p instances of R5;
- R5 represents independently for each occurrence halo, oxo, —CN, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)CR3, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —O(CR2)3NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —NR(CR2)2OR, —N(R)S(O)2NR2, —N(R)S(O)2R, —CR3, —CH2NR2, —CH2NHCH2CH2OR, —CH2CH2C(O)OR, —CH2C(O)NR2, —CH2CH2R, —CH2CH2OR, —NHCH2CH2OR, —NHC(O)R, —CH2OR, —CH2C(O)NH2, —CH2NHC(O)OCR3, a C1-3 alkyl group, a C1-3 haloalkyl group, a C1-3 heteroalkyl group having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 3-6 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- R represents independently for each occurrence hydrogen, hydroxyl, halo, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring;
- n is 0, 1, 2, or 3;
- and
- p is 0, 1, 2, 3 or 4.
10 more elements
A compound represented by Formula II:
- or a pharmaceutically acceptable salt thereof;
- wherein:
- Ring A is a 6-14 membered saturated or partially unsaturated bicyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 6-11 membered saturated or partially unsaturated bicyclic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, an 8-10 membered bicyclic aromatic carbocyclic ring, or phenyl;
- R1 represents independently for each occurrence halo, oxo, —CN, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)CR3, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —O(CR2)3NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —NR(CR2)2OR, —N(R)S(O)2NR2, —N(R)S(O)2R, —CR3, —CH2NR2, —CH2NHCH2CH2OR, —CH2CH2C(O)OR, —CH2C(O)NR2, —CH2CH2R, —CH2CH2OR, —NHCH2CH2OR, —NHC(O)R, —CH2OR, —CH2C(O)NH2, —CH2NHC(O)OCR3, —OCR, C1-4 aliphatic, or C1-4 haloaliphatic, or a cyclic group selected from a 3-8 membered saturated monocyclic carbocyclic ring or a 3-8 membered saturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- R2 is hydrogen, halo, —OH, —CN, cyclopropyl, C1-3 alkyl optionally substituted with a group selected from —OH, —NH2, —NH(CH3), and —N(CH3)2, C1-3 haloalkyl, or C1-3 alkoxy;
- R3 is hydrogen, cyclopropyl, or C1-3 alkyl optionally substituted with a group selected from —OH, —OMe, —NH2, —NH(CH3), and —N(CH3)2;
- R4 is a cyclic group selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7-12 membered saturated or partially unsaturated bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein R4 is substituted with p instances of R5;
- R5 represents independently for each occurrence halo, oxo, —CN, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)CR3, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —O(CR2)3NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —NR(CR2)2OR, —N(R)S(O)2NR2, —N(R)S(O)2R, —CR3, —CH2NR2, —CH2NHCH2CH2OR, —CH2CH2C(O)OR, —CH2C(O)NR2, —CH2CH2R, —CH2CH2OR, —NHCH2CH2OR, —NHC(O)R, —CH2OR, —CH2C(O)NH2, —CH2NHC(O)OCR3, a C1-3 alkyl group, a C1-3 haloalkyl group, a C1-3 heteroalkyl group having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 3-6 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- L1 is a bond, —OCH2—, —O—, —OCH2CH2—, —NHCH2—, —NHCH2CH2—, or —NH—;
- Y represents independently for each occurrence —R, oxo, —OR, —NR2, —OCH2CHF2, —OCH2CH2OH, or —NHCH2CH2OR;
- or two Y groups attached to the same carbon atom can together form a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring or a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- R represents independently for each occurrence —H, —OH, halo, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring;
- n is 0, 1, 2, or 3;
- p is 0, 1, 2, 3 or 4;
- and
- q is 0, 1 or 2.
13 more elements
A compound represented by Formula III:
- or a pharmaceutically acceptable salt thereof;
- wherein:
- Ring A is a 6-14 membered saturated or partially unsaturated bicyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 6-11 membered saturated or partially unsaturated bicyclic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, an 8-10 membered bicyclic aromatic carbocyclic ring, or phenyl;
- R1 represents independently for each occurrence halo, oxo, —CN, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)CR3, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —O(CR2)3NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —NR(CR2)2OR, —N(R)S(O)2NR2, —N(R)S(O)2R, —CR3, —CH2NR2, —CH2NHCH2CH2OR —CH2CH2C(O)OR, —CH2C(O)NR2, —CH2CH2R, —CH2CH2OR, —NHCH2CH2OR, —NHC(O)R, —CH2OR, —CH2C(O)NH2, —CH2NHC(O)OCR3, —OCR, C1-4 aliphatic, or C1-4 haloaliphatic, or a cyclic group selected from a 3-8 membered saturated monocyclic carbocyclic ring or a 3-8 membered saturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- R2 is hydrogen, halo, —OH, —CN, cyclopropyl, C1-3 alkyl optionally substituted with a group selected from —OH, —NH2, —NH(CH3), and —N(CH3)2, C1-3 haloalkyl, or C1-3 alkoxy;
- R3 is hydrogen, cyclopropyl, or C1-3 alkyl optionally substituted with a group selected from —OH, —OMe, —NH2, —NH(CH3), and —N(CH3)2;
- R4 is a cyclic group selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7-12 membered saturated or partially unsaturated bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein R4 is substituted with p instances of R5;
- R5 represents independently for each occurrence halo, oxo, —CN, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)CR3, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —O(CR2)3NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —NR(CR2)2OR, —N(R)S(O)2NR2, —N(R)S(O)2R, —CR3, —CH2NR2, —CH2NHCH2CH2OR, —CH2CH2C(O)OR, —CH2C(O)NR2, —CH2CH2R, —CH2CH2OR, —NHCH2CH2OR, —NHC(O)R, —CH2OR, —CH2C(O)NH2, —CH2NHC(O)OCR3, a C1-3 alkyl group, a C1-3 haloalkyl group, a C1-3 heteroalkyl group having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 3-6 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- X is —O— or —NH—;
- R represents independently for each occurrence —H, —OH, halo, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring;
- n is 0, 1, 2, or 3;
- and
- p is 0, 1, 2, 3 or 4.
10 more elements
A compound represented by Formula IV:
- or a pharmaceutically acceptable salt thereof;
- wherein:
- R1 represents independently for each occurrence halo, oxo, —CN, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)CR3, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —O(CR2)3NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —NR(CR2)2OR, —N(R)S(O)2NR2, —N(R)S(O)2R, —CR3, —CH2NR2, —CH2CH2C(O)OR, —CH2C(O)NR2, —CH2CH2R, —CH2CH2OR, —CH2NHCH2CH2OR, —NHCH2CH2OR, —NHC(O)R, —CH2OR, —CH2C(O)NH2, —CH2NHC(O)OCR3, —OCR, C1-4 aliphatic, or C1-4 haloaliphatic, or a cyclic group selected from a 3-8 membered saturated monocyclic carbocyclic ring or a 3-8 membered saturated monocyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- R2 is hydrogen, halo, —OH, —CN, cyclopropyl, C1-3 alkyl optionally substituted with a group selected from —OH, —NH2, —NH(CH3), and —N(CH3)2, C1-3 haloalkyl, or C1-3 alkoxy;
- R3 is hydrogen, cyclopropyl, C1-3 alkyl optionally substituted with a group selected from —OH, —OMe, —NH2, —NH(CH3), and —N(CH3)2;
- R4 is a cyclic group selected from a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7-12 membered saturated or partially unsaturated bicyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 7-12 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein R4 is substituted with p instances of R5;
- R5 represents independently for each occurrence halo, oxo, —CN, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)CR3, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —O(CR2)3NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —NR(CR2)2OR, —N(R)S(O)2NR2, —N(R)S(O)2R, —CR3, —CH2NR2, —CH2NHCH2CH2OR, —CH2CH2C(O)OR, —CH2C(O)NR2, —CH2CH2R, —CH2CH2OR, —NHCH2CH2OR, —NHC(O)R, —CH2OR, —CH2C(O)NH2, —CH2NHC(O)OCR3, a C1-3 alkyl group, a C1-3 haloalkyl group, a C1-3 heteroalkyl group having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 3-6 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 3-6 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
- R represents independently for each occurrence —H, —OH, halo, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring;
- n is 0, 1, or 2;
- and
- p is 0, 1, 2, 3 or 4.
8 more elements
A compound in Table 1 herein, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.